On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined ‘Closing Bell Overtime’ on CNBC to talk about the latest round of tariff threats. President Trump reiterated his stance on the August 1 deadline for new tariffs and stated on Truth Social that “no extensions will be granted.” Still, market volatility remained low, and stocks have been stable. Beschloss believes that tariffs themselves are not inherently negative; they can be useful in promoting more equitable trade, especially when other countries engage in unfair trade practices. The main concern lies in the way that tariff changes are being communicated and the accompanying drama.

Beschloss particularly highlighted the President’s mention of a potential 100% tariff on pharmaceuticals down the line, which she described as potentially disastrous for every person due to the essential nature of these products and the long production times for pharmaceutical companies within the US She stressed that most companies require greater certainty regarding tariffs, permitting, and regulations before committing to production in the US. According to Grand View Research, the global pharmaceutical market size was estimated at $1.645 trillion in 2024 and is projected to reach $2.350 trillion by 2030, growing at a CAGR of 6.12% from 2025 to 2030. The market is driven by rising chronic disease prevalence, aging populations, and increased healthcare spending.

That being said, we’re here with a list of the 13 best low priced pharma stocks to buy now.

Methodology

We sifted through the Finviz stock screener to compile a list of the top pharma stocks under $20 as of July 14. We then selected the 13 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q1 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

13 Best Low Priced Pharma Stocks to Buy Now

13. Viatris Inc. (NASDAQ:VTRS)

Share Price as of July 14: $9.14

Number of Hedge Fund Holders: 28

Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease/COPD.

Yupelri is the first ever once-daily nebulized long-acting muscarinic antagonist/LAMA approved in China for COPD. Yupelri’s mechanism of action involves inhibiting M3 receptors in the smooth muscle, leading to bronchodilation.

This milestone triggers a one-time payment of $7.5 million from Viatris to Theravance Biopharma Inc. (NASDAQ:TBPH), which is expected in Q3 2025. Theravance Biopharma is also eligible to receive up to an additional $37.5 million in sales-related milestones and escalating royalties ranging from 14% to 20% on net sales of Yupelri in China.

Viatris Inc. (NASDAQ:VTRS) is a healthcare company that operates in 4 segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Theravance Biopharma Inc. (NASDAQ:TBPH) is a biopharmaceutical company that develops and commercializes medicines in the US.

12. Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Share Price as of July 14: $1.58

Number of Hedge Fund Holders: 35

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now. On June 23, Aclaris Therapeutics initiated a placebo-controlled Phase 1a/1b program for its investigational bispecific antibody, called ATI-052. This program follows the recent IND clearance from the US FDA for ATI-052.

The Phase 1a portion will involve single ascending dose/SAD and multiple ascending dose/MAD studies in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ATI-052. ATI-052 is designed as a potential best-in-class bispecific anti-thymic stromal lymphopoietin/TSLP and anti-interleukin-4 receptor/IL-4R antibody.

The design allows for high binding affinity and dual blockade of both upstream TSLP receptor signal transduction and downstream IL-4R activation. The dual targeting selectively inhibits central proinflammatory pathways involved in Th2-mediated inflammation and allergic diseases by blocking TSLP, which is at the top of the inflammatory cascade, and both downstream IL-4 and IL-13, which are key cytokines in these conditions.

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company that develops novel drug candidates for immune-inflammatory diseases in the US.

11. Arvinas Inc. (NASDAQ:ARVN)

Share Price as of July 14: $7.87

Number of Hedge Fund Holders: 37

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting Chimera/PROTAC B-cell lymphoma 6 protein (BCL6) degrader, called ARV-393, at the European Hematology Association/EHA 2025 Congress in Milan, Italy. BCL6 drives B-cell lymphomas.

The studies highlighted ARV-393’s single-agent activity. In a patient-derived xenograft/PDX model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI, also known as AITL), derived from a patient who relapsed post-chemotherapy, ARV-393 substantially reduced tumor burden in the peripheral blood, bone marrow, and spleen.

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy achieved robust tumor growth inhibition/TGI of at least 95% in two PDX models of transformed follicular lymphoma/tFL.

Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that discovers, develops, and commercializes therapies to degrade disease-causing proteins.

10. Biohaven Ltd. (NYSE:BHVN)

Share Price as of July 14: $14.19

Number of Hedge Fund Holders: 37

Biohaven Ltd. (NYSE:BHVN) is one of the best low priced pharma stocks to buy now. Earlier on June 10, Bexorg Inc., which is a techbio company focused on central nervous system/CNS disorders, announced a multi-program research collaboration with Biohaven. The partnership aims to identify, de-risk, and advance next-gen therapies for CNS disorders.

This collaboration centers on Bexorg’s novel whole-brain discovery platform. The unique technology was developed by Bexorg’s founders at Yale University and is capable of perfusing isolated, cadaver human and pig brains with custom-made artificial blood. This process restores metabolic and molecular activity for prolonged periods, which allows Bexorg to extract high-resolution transcriptomic, proteomic, and metabolic insights in disease-relevant states.

By using this information, Bexorg is building physiologically relevant datasets in human neurodegeneration, which are crucial for ML and AI-centered CNS drug discovery and development. The platform’s ability to collect longitudinal data provides an advantage over other preclinical models in neuroscience by enabling the validation of new targets and biomarkers and the understanding of pharmacokinetic and pharmacodynamic profiles.

Biohaven Ltd. (NYSE:BHVN) discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.

9. Wave Life Sciences Ltd. (NASDAQ:WVE)

Share Price as of July 14: $7.84

Number of Hedge Fund Holders: 38

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best low priced pharma stocks to buy now. From June 20 to 23, Wave Life Sciences presented preclinical data for WVE-007, which is its investigational GalNAc-siRNA targeting INHBE mRNA, at the American Diabetes Association’s 85th Annual Scientific Sessions in Chicago.

The oral presentation was delivered on June 21 and highlighted WVE-007 as a potential novel and distinct obesity treatment designed to induce healthy weight loss by reducing fat while preserving muscle mass. WVE-007 functions by silencing INHBE mRNA, which in turn reduces the production of Activin E protein. Activin E is a lipolysis suppressor that is upregulated in obesity. By inhibiting Activin E, WVE-007 promotes lipolysis, or fat breakdown.

Human genetics provides strong support for INHBE as a therapeutic target. Individuals with a protective loss-of-function variant in one copy of the INHBE gene exhibit a healthier cardiometabolic profile, which includes less abdominal fat, lower triglycerides, and reduced risk of type 2 diabetes/T2D and cardiovascular disease/CAD. These individuals also show favorable associations with liver traits, such as reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), without impacting liver fat.

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that designs, develops, and commercializes ribonucleic acid/RNA medicines through PRISM, which is a discovery and drug development platform.

8. Liquidia Corporation (NASDAQ:LQDA)

Share Price as of July 14: $14.48

Number of Hedge Fund Holders: 39

Liquidia Corporation (NASDAQ:LQDA) is one of the best low priced pharma stocks to buy now. On June 24, Liquidia announced the receipt of an additional $50 million from Healthcare Royalty/HCRx. The funding followed the US District Court for the Middle District of North Carolina denying United Therapeutics Corp.’s (NASDAQ:UTHR) request for a preliminary injunction and temporary restraining order, and the subsequent first commercial sale of YUTREPIA (treprostinil) inhalation powder.

Under the terms of their financing agreement, Liquidia received a total of $175 million out of a potential $200 million from HCRx. An additional $25 million may become available upon mutual agreement if Liquidia’s aggregate net sales of YUTREPIA exceed $100 million by June 30, 2026. The $50 million received is subject to a fixed payment schedule through 2033, with total payments to HCRx capped at 175% of the funded amounts.

A true-up payment may be required if HCRx’s internal rate of return for this $50 million falls below a 13% minimum threshold when the cap is reached. These funds will be used to accelerate YUTREPIA’s commercial launch. YUTREPIA is an inhaled dry-powder formulation of treprostinil, a prostacyclin analog, delivered via a convenient, palm-sized device. It was designed using Liquidia’s proprietary PRINT technology.

Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that develops, manufactures, and commercializes various products for unmet patient needs in the US.

United Therapeutics Corp. (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases.

7. Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)

Share Price as of July 14: $3.05

Number of Hedge Fund Holders: 40

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best low priced pharma stocks to buy now. On June 30, Rocket Pharmaceuticals announced that the US FDA cleared its Investigational New Drug/IND application for RP-A701. RP-A701 is a first-in-class AAVrh.74-based gene therapy candidate designed to treat BAG3-associated Dilated Cardiomyopathy (BAG3-DCM).

BAG3-DCM is a rare and inherited heart condition caused by mutations in the BAG3 gene (Bcl2-associated athanogene 3). This leads to early-onset, rapidly progressing heart failure characterized by progressive ventricular enlargement and impaired systolic function, resulting in high morbidity and premature mortality.

A loss of BAG3 leads to the accumulation of misfolded and damaged proteins, impairing the heart’s ability to contract. Rocket Pharmaceuticals estimates that ~30,000 individuals in the US are affected by BAG3-DCM. Current therapies don’t prevent disease progression and are associated with complications.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is a late-stage biotechnology company that develops gene therapies for rare diseases in the US.

6. Viridian Therapeutics Inc. (NASDAQ:VRDN)

Share Price as of July 14: $17.14

Number of Hedge Fund Holders: 40

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 THRIVE clinical trial of veligrotug (“veli”). Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody being developed for active thyroid eye disease/TED, which is an autoimmune condition that causes inflammation, growth, and damage to tissues around and behind the eye.

The THRIVE Phase 3 clinical trial in active TED evaluated 5 infusions of veligrotug or placebo administered every 3 weeks, with the primary topline analysis conducted at week 15, and patients followed through week 52. The new data reveal strong durability: 70% (21 out of 30) of veligrotug-treated patients in THRIVE who were proptosis responders at week 15 and continued follow-up to week 52, maintained their proptosis response.

The safety profile remained consistent during the follow-up period, with the vast majority of adverse events reported at the week 15 primary analysis having resolved by week 52. Veligrotug recently received Breakthrough Therapy Designation/BTD from the FDA, which supports its eligibility for Priority Review.

Viridian Therapeutics Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases.

5. Fortrea Holdings Inc. (NASDAQ:FTRE)

Share Price as of July 14: $5.01

Number of Hedge Fund Holders: 41

Fortrea Holdings Inc. (NASDAQ:FTRE) is one of the best low priced pharma stocks to buy now. On June 24, Fortrea announced a collaboration with Emery Pharma, which is an analytical and bioanalytical CRO. The partnership aims to provide rapid, lot-by-lot testing for 1-methyl-4-nitrosopiperazine/MNP in rifampin. The goal is to ensure that MNP impurities are below the Acceptable Intake/AI Limit set by US FDA guidelines, thereby enabling the continued use of rifampin in drug-drug interaction/DDI studies.

Rifampin is a commonly used antibiotic and has historically been a preferred agent in DDI studies due to its safety and tolerability profile, particularly for inducing the CYP3A4 isoenzyme.

In 2021, the FDA discovered that all tested batches of rifampin contained some levels of MNP that exceeded accepted limits. Then later in 2023, the FDA updated its guidance and raised the acceptable MNP limit for rifampin.

Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

4. Geron Corporation (NASDAQ:GERN)

Share Price as of July 14: $1.34

Number of Hedge Fund Holders: 41

Geron Corporation (NASDAQ:GERN) is one of the best low priced pharma stocks to buy now. Earlier on May 28, Geron Corporation presented new data on RYTELO (imetelstat) at the 2025 American Society of Clinical Oncology/ASCO Annual Meeting and the European Hematology Association/EHA 2025 Congress. These presentations underscored the efficacy and safety of RYTELO across patients with lower-risk myelodysplastic syndromes/LR-MDS with transfusion-dependent anemia and provided updates on its myelofibrosis/MF program.

RYTELO is a first-in-class oligonucleotide telomerase inhibitor that is approved in the US for adult patients with low-to-intermediate-1 risk LR-MDS with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks, who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). It is administered as a 2-hour intravenous infusion every 4 weeks.

RYTELO also received marketing authorization in the European Union on March 11 this year as a monotherapy for adults with transfusion-dependent anemia due to very low, low, or intermediate-risk LR-MDS without an isolated deletion 5q cytogenetic (non-del 5q) abnormality, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The drug works by inhibiting telomerase enzymatic activity, which is often increased in malignant bone marrow cells, leading to telomere shortening and induction of malignant cell death.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutic products for oncology.

3. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX)

Share Price as of July 14: $8.41

Number of Hedge Fund Holders: 42

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and Phase 2b clinical trials of avexitide for post-bariatric hypoglycemia/PBH at the Endocrine Society’s annual meeting (ENDO 2025).

Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist and has received FDA Breakthrough Therapy designation for PBH. PBH is a complication that can arise after bariatric surgery, such as Roux-en-Y gastric bypass.

There are currently no FDA-approved treatments for PBH. Avexitide works by binding to the GLP-1 receptor on pancreatic islet beta cells, blocking the effect of excessive GLP-1 and thus mitigating hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. Avexitide has generally been well-tolerated with a favorable safety profile across all trials. Amylyx expects to complete recruitment for the LUCIDITY trial this year, with topline data anticipated in H1 2026.

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatment options for neurodegenerative diseases and endocrine conditions in the US.

2. Centessa Pharmaceuticals (NASDAQ:CNTA)

Share Price as of July 14: $15.13

Number of Hedge Fund Holders: 43

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best low priced pharma stocks to buy now. On July 4, Nxera Pharma Co. Ltd., which develops and sells pharmaceutical products, announced that it is set to receive $4.8 million in milestone payments from Centessa Pharmaceuticals. These payments stem from their existing research collaboration and followed Centessa’s initiation of clinical development for ORX142, which is a novel orexin receptor 2 (OX2R) agonist.

The initiation follows the recent clearance of an Investigational New Drug/IND application by the US FDA for a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, highly potent, and selective OX2R agonist being developed by Centessa for the treatment of specific neurological and neurodegenerative disorders.

OX2R agonists are a class of compounds designed to activate orexin receptors, which play a role in regulating wakefulness, arousal, and stabilizing sleep-wake transitions. IND clearance by the FDA grants authorization to administer an investigational drug to humans in a clinical study, which allows for the collection of safety and effectiveness data.

Centessa Pharmaceuticals (NASDAQ:CNTA) is a clinical-stage pharmaceutical company that discovers, develops, and delivers medicines.

1. Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Share Price as of July 14: $19.23

Number of Hedge Fund Holders: 47

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, Sarepta Therapeutics started facing a temporary suspension of shipments for ELEVIDYS, which is its gene therapy for Duchenne muscular dystrophy/DMD, specifically for non-ambulatory patients. This decision was announced around June 16 and followed two reported cases of fatal acute liver failure in non-ambulatory patients who received the treatment.

The most recent death involved a 15-year-old patient. These severe side effects have led Sarepta to pause the ENVISION Phase 3 confirmatory trial (SRP-9001-303), which includes both older ambulatory and non-ambulatory individuals, to allow for protocol updates and regulatory discussions.

DMD primarily affects males, with symptoms typically appearing between the ages of 2 and 3. It progresses rapidly and leads to the gradual loss of muscle function in the skeletal, heart, and lung muscles. DMD is caused by a mutation in the DMD gene, which is responsible for producing dystrophin, a protein vital for muscle cell integrity.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.